CVS Health Corp (NYSE:CVS) – Stock analysts at Leerink Swann raised their FY2019 earnings estimates for shares of CVS Health in a research note issued on Thursday, September 20th, according to Zacks Investment Research. Leerink Swann analyst D. Larsen now expects that the pharmacy operator will earn $7.55 per share for the year, up from their prior estimate of $7.45. Leerink Swann has a “Outperform” rating and a $80.00 price objective on the stock.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 8th. The pharmacy operator reported $1.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.08. CVS Health had a return on equity of 18.25% and a net margin of 1.61%. The business had revenue of $46.71 billion for the quarter, compared to the consensus estimate of $46.34 billion. During the same period last year, the business earned $1.33 EPS. The firm’s revenue was up 2.2% compared to the same quarter last year.

A number of other research analysts also recently weighed in on the company. Bank of America raised their price objective on CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, September 17th. ValuEngine downgraded CVS Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 4th. Royal Bank of Canada raised their price objective on CVS Health to $101.00 and gave the company an “outperform” rating in a research note on Tuesday, September 18th. Citigroup reissued a “buy” rating and issued a $81.00 price objective on shares of CVS Health in a research note on Monday, July 9th. Finally, Morgan Stanley cut their price objective on CVS Health from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. CVS Health has an average rating of “Buy” and a consensus target price of $86.31.

Shares of CVS stock traded up $1.39 during trading on Friday, reaching $74.58. The company had a trading volume of 9,475,196 shares, compared to its average volume of 8,231,727. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.87 and a current ratio of 2.34. CVS Health has a one year low of $60.14 and a one year high of $83.88. The company has a market capitalization of $80.14 billion, a price-to-earnings ratio of 12.64, a PEG ratio of 1.05 and a beta of 1.02.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVS. Camarda Financial Advisors LLC acquired a new stake in CVS Health in the 2nd quarter valued at $102,000. Canton Hathaway LLC acquired a new stake in CVS Health in the 3rd quarter valued at $126,000. Kiley Juergens Wealth Management LLC acquired a new stake in CVS Health in the 2nd quarter valued at $103,000. Quantbot Technologies LP acquired a new stake in CVS Health in the 1st quarter valued at $103,000. Finally, Legacy Advisors LLC boosted its stake in CVS Health by 7,100.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock valued at $116,000 after buying an additional 1,775 shares in the last quarter. Institutional investors and hedge funds own 82.75% of the company’s stock.

In other news, EVP Kevin Hourican sold 8,564 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $75.00, for a total transaction of $642,300.00. Following the sale, the executive vice president now directly owns 12,135 shares in the company, valued at $910,125. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Eva C. Boratto sold 13,311 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.16, for a total value of $1,027,076.76. Following the sale, the executive vice president now owns 55,162 shares in the company, valued at $4,256,299.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,409 shares of company stock worth $3,392,097. Company insiders own 0.53% of the company’s stock.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.68%. The ex-dividend date is Tuesday, October 23rd. CVS Health’s dividend payout ratio is currently 33.90%.

About CVS Health

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

See Also: What is a Call Option?

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.